Haemonetics HAE Business Segments
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| Net revenues by Business | |||||
| Blood Center | $221.27M-15.3% | $261.12M— | —— | —— | |
| Hospital | $588.3M+4.3% | $564.27M— | —— | —— | |
| Plasma | $524.46M-2.0% | $535.43M— | —— | —— | |
| Operating Income by Business | |||||
| Blood Center | $49.98M-5.4% | $52.82M— | —— | —— | |
| Hospital | $103.74M+16.6% | $88.98M— | —— | —— | |
| Plasma | $184.8M+0.2% | $184.51M— | —— | —— | |
| Costs incurred, net of reversals by Business | |||||
| Blood Center | -$558K-112% | $4.74M-15.4% | $5.61M— | $0+100% | |
| Hospital | $1.33M-20.3% | $1.66M-56.9% | $3.86M+2,241% | $165K+277% | |
| Plasma | $448K— | —— | $1.02M— | —— | |
| SG&A by Business | |||||
| Blood Center | $54.13M-9.8% | $60.02M-10.9% | $67.34M-9.0% | $74.02M— | |
| Hospital | $247.25M+2.3% | $241.76M+15.3% | $209.68M+15.6% | $181.37M— | |
| Plasma | $105.32M+7.0% | $98.42M-10.3% | $109.73M+3.5% | $106.01M— | |
| Cost of goods sold by Business | |||||
| Blood Center | $112.67M-20.9% | $142.51M-13.9% | $165.56M+14.7% | $144.36M— | |
| Hospital | $203.23M+1.9% | $199.5M+19.3% | $167.17M+13.1% | $147.83M— | |
| Plasma | $214.14M-9.7% | $237.05M-10.2% | $264.04M+3.8% | $254.47M— | |
| Total long-lived assets by Business | |||||
| Blood Center | $158.88M— | —— | —— | —— | |
| Hospital | $217.8M— | —— | —— | —— | |
| Plasma | $812.2M— | —— | —— | —— | |
| R&D by Business | |||||
| Blood Center | $4.49M-22.1% | $5.77M-27.5% | $7.96M+81.9% | $4.37M— | |
| Hospital | $34.09M+0.2% | $34.04M+24.9% | $27.24M+17.9% | $23.1M— | |
| Plasma | $20.2M+30.7% | $15.45M+12.0% | $13.8M-6.1% | $14.69M— | |
| Restructuring related costs by Business | |||||
| Blood Center | -$1K-101% | $154K-46.2% | $286K+281% | $75K-86.5% | |
| Hospital | $0-100% | $143K-65.0% | $408K-25.3% | $546K+44.1% | |
| Plasma | $9K-96.8% | $281K-73.2% | $1.05M-24.2% | $1.39M-82.5% | |
| D&A by Business | |||||
| Blood Center | $7.16M-28.9% | $10.08M-24.7% | $13.39M— | —— | |
| Hospital | $57.19M-0.1% | $57.25M+50.2% | $38.11M— | —— | |
| Plasma | $47.37M-1.9% | $48.26M+5.6% | $45.71M— | —— | |
| Currency translation by Business | |||||
| Plasma | $0— | $0— | —— | $0— | |
| Goodwill by Business | |||||
| Blood Center | $108.16M-11.7% | $122.52M— | —— | —— | |
| Hospital | $2.25B+2.4% | $2.2B— | —— | —— | |
| Plasma | $116.17M0.0% | $116.17M— | —— | —— | |
| Total net revenues by Product | |||||
| Plasma | $524.46M-2.0% | $535.43M-6.0% | $569.54M+10.4% | $515.89M+46.8% | |
| Net revenues by Geography | |||||
| Europe | $185.02M+5.3% | $175.66M+9.7% | $160.14M+2.2% | $156.68M-4.2% | |
| Japan | $68.2M+9.3% | $62.41M+7.4% | $58.09M-5.2% | $61.3M-18.9% | |
| Other | $11.42M-41.5% | $19.54M+47.1% | $13.28M+264% | $3.65M-8.4% | |
| Rest of Asia | $87.21M-5.5% | $92.31M-14.2% | $107.54M+3.3% | $104.14M-6.0% | |
| United States | $982.18M-2.8% | $1.01B+4.2% | $970.01M+15.1% | $842.9M+31.8% | |
| Total long-lived assets by Geography | |||||
| Europe | $112.32M— | —— | —— | —— | |
| Japan | $4.38M— | —— | —— | —— | |
| Other | $70.99M— | —— | —— | —— | |
| Rest of Asia | $123.14M— | —— | —— | —— | |
| United States | $878.04M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Haemonetics break its business down?
- Haemonetics (HAE) reports net revenues by business across 3 parts — Blood Center, Hospital and Plasma. Each is extracted from the segment footnotes and tracked over time.
- Where does Haemonetics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Haemonetics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.